This clinical trial wants to find out if using a special bracelet that vibrates gently whenever someone with a nail-biting problem bites their nails can help them stop. The investigators are looking at adults who bite their nails a lot. If this bracelet works, it could make nail-biters bite their nails less and have a better life.
   
The main question the investigators are trying to answer is: "Does the gentle vibration from the bracelet make people bite their nails less?"
   

This research study is for men who have a diagnosis of prostate cancer and have been selected by their physician to receive Pluvicto to treat their cancer.
   

The purpose of this research study is to evaluate the effect of the investigational study drug Efruxifermin (EFX) in treating compensated liver cirrhosis due to nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) and how safe it is to use in people.

 The purpose of this study is to test if an investigational study drug, LMN-201, is safe and effective in treating patients with infection of the lower intestine (the colon) by bacteria called Clostridioides difficile (abbreviated C. difficile or C. diff). Individuals will be asked to be participants in this research study because they have developed an infection of their lower intestine (the colon) by bacteria called Clostridioides difficile (abbreviated C. difficile or C. diff).

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure.

The aim of this study is to find out if using a certain kind of mesh can reduce the chances of hiatal hernias coming back after anti-reflux surgery. The mesh used is approved by the U.S. Food and Drug Administration (FDA). 

Participants undergoing antireflux surgery will be assigned to one of two groups, a group that has surgery with mesh, or a group that has surgery without mesh. 

Any required post-surgical visits will be standard-of-care visits that participants would have regardless of study participation.  

This clinical trial is for men and women who have Multiple Myeloma that is either unresponsive to prior treatment or has relapsed.
   

This clinical trial is for men and women who have completed all the requirements for a corresponding parent treatment study of AAA617. 
   
In this study, participants will need to visit the study doctor about 2 times per year (every 6 to 8 months) which will include having routine blood and urine testing done at each visit.
   
Participation is expected to last up to 10 years from the first dose of AAA617 received on the parent treatment study.

This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory).

CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). CB-012 is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA).

This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of participants with unresectable Hepatocellular Carcinoma (HCC, a.k.a. liver cancer).

Eye90 is comprised of tiny glass beads containing yttrium-90 (Y90), a radioactive material. The beads are delivered in and around the tumor(s) through a tiny catheter placed through the artery of the groin or wrist and into one or more branches of the artery of the liver under x-ray camera guidance.